我院2004～2007年异基因干细胞移植住院患者用药分析

目的:评价我院异基因干细胞移植住院患者的用药情况。方法:采用回顾性方法,对我院2004～2007年24例异基因干细胞移植住院患者的用药品种、费用等进行分析。结果:干细胞移植住院患者平均住院药品费用为(66418.56±24381.73)元,占总住院费用的61.69%。销售金额排序列前20位的药品主要是免疫系统药、影响血液及造血系统药、抗肿瘤药等。用药频度排序列前20位的药品主要集中在免疫抑制剂和抗肿瘤药及辅助药,大多数药品的药物利用指数≤1。结论:我院干细胞移植患者住院期间用药基本合理。

Drug Use in the Inpatients Undergoing Allogeneic Stem Cell Transplantation

OBJECTIVE： To analyze the drug use in the inpatients undergoing allogenic stem cell transplantation. METHODS： The drug use in 24 inpatients undergoing allogenic stem cell transplantation from 2004 to 2007 were analyzed retrospectively in respect of drug variety and drug cost etc. RESULTS： The average drug cost for the inpatients undergoing stem cell transplantation was（66 418.56 ~ 24 381.73）yuan, comprising 61.69% of the total cost of hospitalization. The top 20 drugs in terms of consumption sum were mainly drugs for immune system, drugs affecting hematological and hematopoietic system and anti - tumor drugs etc. The top 20 drugs in terms of DDDs were mainly immunosuppressants, anti - tumor drugs and adjunctive drugs, with DUI≤1 for the majority of the drugs. CONCLUSION： The drug use in the inpatients undergoing allogenic stem Cell transplantation in our hospital was rational on the whole.